Compare Medtronic PLC (MDT) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Smith & Nephew plc — how do they compare? Medtronic PLC trades at $90.31 (market cap $116.07B), while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: Medtronic PLC is far larger — about 9.3× Smith & Nephew plc's market cap, and Medtronic PLC pays the higher dividend (3.18%). Which is the better fit depends on your goals.
| MDT | SNN | |
|---|---|---|
Market Cap | $116.07B | $12.54B |
Sector | Health | Health |
52-Week High | $105.35 | $38.70 |
52-Week Low | $73.75 | $28.73 |
Enterprise Value | $134.82B | $15.57B |
Dividend Yield | 3.18% | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $89.41, up 2.58% on the day, reflecting positive momentum. The stock exhibits bullish technical signals with strong moving average support and a consensus analyst price target of $98.75. Fundamentally, the company reported revenue of $33.54B for 2025 with a net income margin of 13.2%, and has consistently beaten EPS estimates in recent quarters. Recent news highlights institutional acquisitions and positive developments in medical technology platforms.
The outlook for MDT is positive, driven by earnings beats, robust cash flow, and growth in cardiac and robotic surgery segments. Key opportunities include undervaluation relative to analyst targets and dividend stability. Risks involve rising debt levels and competitive pressures in the medtech sector. The stock presents a compelling case for growth-oriented income investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
